ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1338

Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start

Mojca Frank-Bertoncelj1, Oliver Distler 2, Tim Killeen 3, Kenneth Kwok 4, Lisy Wang 5, Caroline Ospelt 1 and Adrian Ciurea 1, 1University Hospital Zürich, Zürich, Switzerland, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3Pfizer AG, Zürich, Switzerland, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Groton, CT

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Clinical, methotrexate (MTX), rheumatoid arthritis (RA) and tofacitinib

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite systemic inflammatory cues, RA affects synovial joints variably. Tofacitinib is an oral JAK inhibitor for the treatment of RA. Previous post hoc analyses of data from ORAL Standard and ORAL Strategy showed differences in the degree/rate at which joints respond to tofacitinib ± MTX and adalimumab + MTX.1 However, clear patterns relating to specific agents were generally not seen, possibly as most patients (pts) received combination therapy with MTX. Here, we further characterize joint-specific responses to tofacitinib monotherapy and MTX using data from the Phase 3 study ORAL Start (NCT01039688).

Methods: This was a post hoc analysis of Month (M)3, 6, and 12 data from ORAL Start in which pts with newly diagnosed, active RA received tofacitinib 5 or 10 mg twice daily (BID), or MTX (starting dose 10 mg/week and titrated up to 20 mg/week). A paired joint pathology score (PJPS), a combination of bilateral tender/swollen joint counts ranging from 0 (neither) to 4 (both sides tender/swollen), was calculated. Percentage changes from baseline in PJPS (%ΔPJPS) for each joint were presented in a heat map. To show treatment-specific effects at each joint, differences in %ΔPJPS for each tofacitinib dose, minus the MTX group, were calculated and presented in a further heat map. Joint damage in the hand PIP joints, MCP joints, wrist, and foot IP and MTP joints was assessed using the modified Total Sharp Score (mTSS). For each component of the mTSS composite score (erosion, joint space narrowing) and total score, a radiographic PJPS (rPJPS; combination of bilateral mTSS subscores in each joint group) was calculated and mean ΔrPJPS at M12 for each joint group presented. Statistical comparisons between tofacitinib vs MTX were performed using a repeated measures mixed model.

Results: Across treatment arms, all joints showed a treatment response (%ΔPJPS ranged from -95% to -39%), with responses generally improving over time (Figure 1). As previously reported,1 irrespective of treatment, the wrist, knee, and ankle responded less well than other joints. Differences in %ΔPJPS showed better responses for tofacitinib vs MTX in most joint locations, excepting some foot joints (Figure 2). Radiographic progression was minimal in all 4 joint groups (hand PIP joints, MCP joints, wrist, and foot IP and MTP joints) with both tofacitinib doses (Figure 3). The greater %ΔPJPS seen in the foot for MTX vs tofacitinib did not translate into improved radiographic outcomes at M12: ΔrPJPS in the foot were significantly worse for MTX vs tofacitinib across each endpoint (Figure 3), as were ΔrPJPS in the MCP joints.

Conclusion: Wide variation in RA joint-specific responses to tofacitinib 5 and 10 mg BID, and MTX, was seen in this post hoc analysis. Tofacitinib was generally more effective than MTX in all joints, except some foot joints. Enhanced efficacy in the distal lower limb has not been described with MTX before. Radiographic progression was minimal in the tofacitinib arms, while in the MTX arm, significantly more radiographic progression was observed in the MCP joints and foot.

  1. Ciurea A et al. Ann Rheum Dis 2019; In Press.

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by K Woollcott of CMC Connect and funded by Pfizer Inc.


Disclosure: M. Frank-Bertoncelj, Kurt und Senta Herrmann Foundation, 2, Promedica Foundation, 2; O. Distler, A. Menarini, 5, Abbvie, Acceleron, 5, Acceleron Pharma, 5, Actelion, 2, 5, 8, Actelion Pharmaceuticals, 2, 5, 8, 9, Amgen, 5, AnaMar, 2, 5, Bayer, 2, 5, 8, 9, Biogen Idec, 2, 5, Blade Therapeutics, 5, Boehringer Ingelheim, 2, 5, 8, 9, Catenion, 5, 9, ChemomAb, 2, 5, ChemomAB, 5, CSL Behring, 5, Ergonex, 5, espeRare Foundation, 2, 5, Genentech/Roche, 2, 5, GlaxoSmithKline, 5, GSK, 2, 5, Holds Patent mir-29 for the treatment of systemic sclerosis, 9, Inventiva, 2, 5, iQvia, 5, Italfarmaco, 2, 5, Italfarmco, 5, Lilly, 2, 5, med, 5, 8, medac, 5, Medac, 2, 5, MedImmune, 2, 5, Medscape, 5, 8, 9, Menarini, 8, Mepha, 8, Mitsubishi Tanabe, 2, 5, Mitsubishi Tanabe Pharma, 2, 5, MSD, 5, 8, Novartis, 2, 5, 8, 9, Patent, 9, Patent issued, 9, Pfizer, 2, 5, 8, Pharmacyclics, 2, 5, Roche, 5, 8, 9, Sanofi, 2, 5, Sinoxa, 2, 5, Target Bio Science, 5, Target BioScience, 5, UCB, 2, 5, 9, UCB in the area of potential treatments of scleroderma and its complications, 2, 5; T. Killeen, Pfizer Inc, 1, 3; K. Kwok, Pfizer Inc, 1, 3; L. Wang, Pfizer Inc, 1, 3; C. Ospelt, Kurt und Senta Herrmann Foundation, 2, Promedica Foundation, 2; A. Ciurea, AbbVie, 5, Celgene, 5, Eli Lilly, 5, Janssen-Cilag, 5, MSD, 5, Novartis, 5, Pfizer, 5, UCB, 5.

To cite this abstract in AMA style:

Frank-Bertoncelj M, Distler O, Killeen T, Kwok K, Wang L, Ospelt C, Ciurea A. Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/joint-specific-responses-to-tofacitinib-and-methotrexate-in-rheumatoid-arthritis-a-post-hoc-analysis-of-data-from-oral-start/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/joint-specific-responses-to-tofacitinib-and-methotrexate-in-rheumatoid-arthritis-a-post-hoc-analysis-of-data-from-oral-start/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology